Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD

No abstract is available for this paper.

• Publication year

  2009

• Venue

  European Respiratory Journal

• Publication date

  2009-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1183/09031936.00115308PMID 19129278
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease.

  2008cited by this paper
• The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.

  2008cited by this paper
• Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD.

  2008cited by this paper
• Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.

  2008cited by this paper
• Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

  2007cited by this paper
• Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD

  2007cited by this paper
• Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

  2007cited by this paper
• Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus‐induced epithelial production of remodelling‐associated growth factors

  2006cited by this paper
• Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells.

  2006cited by this paper
• Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.

  2006cited by this paper
• Inhibition of pyocyanin-potentiated IL-8 release by steroids in bronchial epithelial cells.

  2006cited by this paper
• Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease

  2006cited by this paper
• Inhaled Fluticasone and Salmeterol Suppress Eosinophilic Airway Inflammation in Chronic Obstructive Pulmonary Disease: Relations with Lung Function and Bronchodilator Reversibility

  2006cited by this paper
• Inhibition of chemokine production from human airway smooth muscle cells by fluticasone, budesonide and beclomethasone.

  2004cited by this paper
• Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD.

  2004cited by this paper
• Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma.

  2004cited by this paper
• Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.

  2004cited by this paper
• The nature of small-airway obstruction in chronic obstructive pulmonary disease.

  2004cited by this paper
• Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment.

  2004cited by this paper
• Matrix metalloproteinase-9 in lung remodeling.

  2003cited by this paper
• Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo

  2003cited by this paper
• Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

  2003cited by this paper
• Concentration-dependent effects of mometasone furoate and dexamethasone on foetal lung fibroblast functions involved in airway inflammation and remodeling.

  2003cited by this paper
• Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.

  2003cited by this paper
• Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.

  2003cited by this paper
• The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study.

  2002cited by this paper
• Regulation of the depth and composition of airway surface liquid

  2002cited by this paper
• Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

  2002cited by this paper
• American translation, modification, and validation of the St. George's Respiratory Questionnaire.

  2000cited by this paper
• Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function.

  1999cited by this paper
• The cellular composition of induced sputum in chronic obstructive pulmonary disease.

  1999cited by this paper
• Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease.

  1999cited by this paper
• Severity of airflow limitation is associated with severity of airway inflammation in smokers.

  1998cited by this paper
• Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity.

  1998cited by this paper
• Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema.

  1998cited by this paper
• Regulation of depth and composition of airway surface liquid.

  1997cited by this paper
• Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils.

  1996cited by this paper
• Desensitization of the adenylyl cyclase system in peripheral blood mononuclear cells from patients with asthma three hours after allergen challenge.

  1993cited by this paper
• Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease.

  1993cited by this paper
• The St George's Respiratory Questionnaire.

  1991cited by this paper

• The Impact of Age and Disease Entity on Small Airway Dysfunction in Obstructive Airway Diseases

  2025cites this paper
• Anti-inflammatory effects of tiotropium in COPD: a randomised double-blind trial

  2024influential citation
• The Bronchodilator and Anti‐Inflammatory Effect of Long‐Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper

  2024cites this paper
• Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials

  2022cites this paper
• Monomeric CRP is Elevated in Patients with COPD Compared to Non-COPD Control Persons

  2021cites this paper
• Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies

  2021cites this paper
• The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review

  2021cites this paper
• COPD_A_275943 2065..2076

  2021cites this paper
• Fractional Exhaled Nitric Oxide Guided-Therapy in Chronic Obstructive Pulmonary Disease: A Stratified, Randomized, Controlled Trial.

  2021cites this paper
• Responsivity and Reproducibility of Sputum Inflammatory Biomarkers During COPD Exacerbation and Stable Phases – A Pilot Study

  2021cites this paper
• Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis

  2020cites this paper
• Measurement properties of preference-based measures for economic evaluation in COPD: a systematic review

  2020cites this paper
• Shp2 positively regulates cigarette smoke-induced epithelial mesenchymal transition by mediating MMP-9 production

  2020cites this paper
• The relationship between inflammatory markers and spirometric parameters in ACOS, Asthma, and COPD

  2019cites this paper
• LABAs and p38MAPK Inhibitors Reverse the Corticosteroid-Insensitivity of IL-8 in Airway Smooth Muscle Cells of COPD

  2019cites this paper
• Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment.

  2019cites this paper
• Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease

  2018cites this paper
• Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.

  2018influential citation
• Possible involvement of acetylcholine-mediated inflammation in airway diseases.

  2018cites this paper
• Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis

  2018cites this paper
• Protective effects of tiotropium alone or combined with budesonide against cadmium inhalation induced acute neutrophilic pulmonary inflammation in rats

  2018cites this paper
• Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.

  2018cites this paper
• The Cholinergic Pathways in Inflammation: A Potential Pharmacotherapeutic Target for COPD

  2018cites this paper
• Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis

  2017cites this paper
• Biomarkers of COPD

  2017cites this paper
• The Relationship between Airway Inflammation and Exacerbation in Chronic Obstructive Pulmonary Disease

  2017cites this paper
• Defective Alveolar Macrophage Function in COPD and Novel Treatments to Restore the Defects

  2017cites this paper
• Post-bronchodilator Reversibility of FEV1 and Eosinophilic Airway Inflammation in COPD.

  2017cites this paper
• Chronic obstructive pulmonary disease associated with increased risk of bipolar disorder

  2017cites this paper
• Anti-Inflammatory Effects of Chinese Herbal Medicine on COPD: A Systematic Review

  2016cites this paper
• The Impact of Exogenous Factors on Respiratory Pathogen-Induced Innate Alveolar Macrophage Responses in COPD

  2016cites this paper
• The anti-inflammatory and anti-remodeling effect of tiotropium bromide in the subacute cigarette exposure mouse model

  2016cites this paper
• Once daily Long‐acting beta2‐agonists/Inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease

  2016cites this paper
• The Anti-inflammatory Effect of Alpha-1 Antitrypsin in Rhinovirus-infected Human Airway Epithelial Cells.

  2016cites this paper
• Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling.

  2015cites this paper
• Acetylcholine beyond bronchoconstriction: a regulator of inflammation and remodeling

  2015cites this paper
• Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary Disease

  2015cites this paper
• Long-acting muscarinic antagonists

  2015cites this paper
• Estudio de los efectos de agentes anticolinérgicos y de inhibidores de fosfodiesterasa-5 sobre la estructura pulmonar en un modelo experimental de enfermedad pulmonar obstructiva crónica inducido por humo de tabaco en el cobayo

  2015cites this paper
• Inflammatory markers and mortality among US adults with obstructive lung function

  2015cites this paper
• Cigarette smoke alters non-neuronal cholinergic system components inducing MUC5AC production in the H292 cell line.

  2014cites this paper
• Airway inflammation and tiotropium treatment in stable COPD patients.

  2014cites this paper
• Acute Exacerbations of Chronic Obstructive Pulmonary Disease

  2014cites this paper
• Tiotropium HandiHaler Improves the Survival of Patients with COPD: A Systematic Review and Meta-Analysis

  2014cites this paper
• Effects of aclidinium bromide in a cigarette smoke-exposed Guinea pig model of chronic obstructive pulmonary disease.

  2013cites this paper
• Muscarinic receptor subtype-specific effects on cigarette smoke-induced inflammation in mice

  2013cites this paper
• Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease.

  2013cites this paper
• Inhaled corticosteroids in COPD: pros and cons.

  2013cites this paper
• Can β2‐adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?

  2012cites this paper
• Muscarinic receptor agonists and antagonists: effects on inflammation and immunity.

  2012cites this paper
• Inflammation in COPD: implications for management.

  2012cites this paper
• The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease.

  2012cites this paper
• Long-acting β2 agonists and corticosteroids restore the reduction of histone deacetylase activity and inhibit H2O2-induced mediator release from alveolar macrophages.

  2012cites this paper
• Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.

  2012cites this paper
• Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD.

  2012cites this paper
• Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the

  2011cites this paper
• Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease.

  2011cites this paper
• Inhibition of granulocyte migration by tiotropium bromide

  2011cites this paper
• Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4+CD25+Foxp3+ regulatory T cells in COPD

  2011cites this paper
• Biomarkers of Therapeutic Response in Patients with Chronic Obstructive Pulmonary Disease

  2011cites this paper
• Lung-targeted overexpression of the NF-κB member RelB inhibits cigarette smoke-induced inflammation.

  2011cites this paper
• PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease.

  2011cites this paper
• Ttiotropium increases cytosolic muscarinic M3 receptors and acetylated H3 histone proteins in induced sputum cells of COPD patients

  2010cites this paper
• Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease

  2010cites this paper
• Effect of tiotropium on quality of life in COPD: a systematic review.

  2010cites this paper
• [Systemic inflammation among stable ex smokers with chronic obstructive pulmonary disease].

  2010cites this paper
• Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD.

  2009cites this paper
• Advanced chronic obstructive pulmonary disease (COPD)

  2009cites this paper
• A Stepwise Approach to Management of Stable COPD With Inhaled Pharmacotherapy: A Review

  2009cites this paper